Evidence map›Paper›PMID 39215660›Full record

ReviewJournal of investigative medicine high impact case reports

Atypical Site of Presentation of a Rare Type of SMARCA4-Positive Cutaneous Squamous Cell Carcinoma of the Skin: Case Report and Review of the Literature.

Ruchi Yadav, Shaun Din, Harry Moussaris, Vivek Yadav, Shakthi Raman, Anjula Gandhi, Boris Avezbakiyev, J C Wang

Abstract readCase ReportsReview
In one paragraph

Review in Journal of investigative medicine high impact case reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ruchi YadavBrookdale University Hospital Medical Center, Brooklyn, NY, USA.ORCID 0000-0002-8207-2424
Shaun DinBrookdale University Hospital Medical Center, Brooklyn, NY, USA.
Harry MoussarisBrookdale University Hospital Medical Center, Brooklyn, NY, USA.
Vivek YadavState University of New York Downstate Health Sciences University, Brooklyn, NY, USA.
Shakthi RamanMedical University of Lublin, Poland.
Anjula GandhiBrookdale University Hospital Medical Center, Brooklyn, NY, USA.
Boris AvezbakiyevBrookdale University Hospital Medical Center, Brooklyn, NY, USA.
J C WangBrookdale University Hospital Medical Center, Brooklyn, NY, USA.ORCID 0000-0002-9623-6645

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cutaneous squamous cell carcinoma (cSCC) comprises 20% of cases of nonmelanoma skin cancers in the United States. In total, 3% to 5% of squamous cell carcinoma (SCC) are metastatic at the time of presentation, associated with significant mortality due to a lack of standardized treatment options. In total, 95% of these tumors are amenable to the initial standard of treatment, which is surgical resection. However, a small percentage of them require systemic therapy as they are either locally advanced to regional lymph nodes or have distant metastasis. The common sites of presentation of cSCC are the scalp and the face with predictable spread to the intra-parotid, upper jugular, and perifacial lymph nodes. In our case report, however, our patient had a large lump lesion on the upper back, an unusual site of presentation of cSCC, with locally advanced metastasis to the left axillary lymph nodes. Subsequently, the tumor marker study revealed a positive SMARCA4 variant (the essential ATPase subunit of the Switch (SWI)/Sucrose Nonfermenting (SNF) chromatin-remodeling complex) that is even rarer in the context of cSCC. Furthermore, abnormalities in SWI/SNF chromatin-remodeling complex subunits have shown promising results as a target therapy for immune checkpoint inhibitor (ICI) therapy. We present an atypical presentation site of locally advanced rare variant SMARCA4-positive cSCC in a patient who received treatment with chemoradiation and systemic therapy with ICI after primary surgical resection. To date, only 2 cases of SMARCA4-positive cSCC were found in the literature with no details of the treatment received. Our case is unique in its atypical site of presentation as well as showing partial response to radiotherapy (RT) and systemic therapy with ICI.

Indexed as

Carcinoma, Squamous CellDNA HelicasesNuclear ProteinsSkin NeoplasmsTranscription FactorsAgedHumansLymphatic MetastasisMaleDNA HelicasesNuclear ProteinsSMARCA4 protein, humanTranscription Factorscutaneous squamous cell carcinomaimmune checkpoint therapySMARCA4 positivesystemic chemotherapy

Identifiers

PMID39215660
PMCPMC11366091

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.